Mumbai, April 23, 2026: Gujarat Themis Biosyn Limited (GTBL) has signed an asset purchase agreement to acquire a global portfolio of anti-tuberculosis (TB) and anti-infective brands from Sanofi, marking a significant step in its strategy to expand internationally and move up the pharmaceutical value chain.
The acquisition, valued at €158 million, will be funded through a mix of debt and equity and is expected to close by the end of Q3 FY27, subject to regulatory approvals including antitrust and foreign direct investment clearances.
Portfolio Details
The transaction includes 13 established branded generic products with a presence across more than 55 countries spanning Europe, the Middle East, and Africa. The portfolio generated net sales of approximately €62 million in 2025. As part of the deal, GTBL will acquire marketing authorizations, brands, regulatory dossiers, inventory, and associated commercial rights. However, no manufacturing facilities or employees will be transferred, making the acquisition asset-light and capital efficient.
Strategic Rationale
The acquisition aligns with GTBL’s strategy to strengthen its global pharmaceuticals platform and expand its footprint in the anti-infective segment. By acquiring finished dosage formulations, the company aims to move forward in the value chain from its existing capabilities in fermentation-based intermediates and active pharmaceutical ingredients (APIs). The deal is also expected to provide immediate access to regulated and semi-regulated markets, enhancing GTBL’s global reach while offering opportunities for backward integration and margin improvement.
Growth Opportunities
The acquired portfolio operates at healthy gross margins, with potential for further upside through operational efficiencies and integration with GTBL’s existing manufacturing capabilities. The company also sees opportunities in expanding into underpenetrated markets, developing new formulations, and optimizing distribution networks. Additionally, the portfolio includes well-established brands with strong clinical relevance, offering a stable revenue base and scope for sustained growth.
Management Commentary
Dr. Sachin Patel, Managing Director of GTBL, described the acquisition as a strategic milestone in the company’s evolution toward a high-margin, integrated pharmaceutical platform. He highlighted that controlling the value chain from fermentation to finished products would help improve profitability, reduce supply chain risks, and expand the company’s global footprint.
Industry Context
The move comes amid continued global focus on combating tuberculosis and antimicrobial resistance. International health initiatives targeting TB elimination by 2030, along with increasing reliance on mature antibiotics, are expected to sustain demand for anti-infective therapies.
Outlook
The transaction is expected to be earnings accretive for GTBL, supported by profitable branded generics, vertical integration, and operating leverage. The acquisition positions the company to strengthen its presence in global healthcare markets while building a more diversified and scalable pharmaceutical business.